How long do new medicines take to reach Canadian patients after companies file a submission: A cohort study
Studies of the delay between when companies file a New Drug Submission (NDS) and when drugs reach Canadian patients typically focus on the time in the regulatory review process and do not analyze the time between when approval is granted and the drug is available for purchase (company decision time)...
Gespeichert in:
| Veröffentlicht in: | PloS one 2020-11, Vol.15 (11), p.e0240966-e0240966 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0240966 |
|---|---|
| container_issue | 11 |
| container_start_page | e0240966 |
| container_title | PloS one |
| container_volume | 15 |
| creator | Lexchin, Joel |
| description | Studies of the delay between when companies file a New Drug Submission (NDS) and when drugs reach Canadian patients typically focus on the time in the regulatory review process and do not analyze the time between when approval is granted and the drug is available for purchase (company decision time). This study looks at the length of the two different time periods. Secondarily, it examines whether there is a difference in these time periods for drugs that received a standard review and those that received an expedited review.
A list of all New Active Substances approved in Canada between January 1, 2014 and December 31, 2018 was compiled and the dates when the companies applied for a NDS, the dates when the drugs received a market authorization (Notice of Compliance, NOC) and whether the drugs received a standard review or an expedited review were recorded. The date of original marketing comes from Health Canada's Drug Product Database. Times in days were calculated between NDS and NOC (review time), between NOC and the marketing date (company decision time) and between NDS and the marketing date (total time). The company decision time as a percent of the total time was calculated for all drugs. Times were compared between standard and expedited review drugs using a two-tailed t-test.
One hundred and fifty-seven drugs were analyzed, 98 had a standard review and 59 had a priority review. Over 18% of the total time was due to company decisions. All three times were significantly lower for expedited review drugs versus standard review drugs as was the percent of total time due to company decision- 14.4% (95% CI 11.0, 17.8) versus 21.2% (95% CI 17.6, 24.8), p = 0.0102 (t-test).
Over 18% of the total time between when companies file for drug approval until the drug is available is due to decisions made by companies. Company decision times are shorter for drugs with expedited approvals compared to drugs with standard approvals. |
| doi_str_mv | 10.1371/journal.pone.0240966 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2456844673</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A640345259</galeid><doaj_id>oai_doaj_org_article_4c48570181a44bf4bd1827fc2458fba1</doaj_id><sourcerecordid>A640345259</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-8f1ed2d13564a73fc5996305668921484cb8068eabbb943cd4842f2df2a0ff6a3</originalsourceid><addsrcrecordid>eNqNk11rFDEUhgdRbK3-A9GAIHqxa74mM-OFsCxqFwoFv27DmUyym3Y22SYZa_-92e607EovJBcJyXPe5Lw5pyheEjwlrCIfLvwQHPTTjXd6iinHjRCPimPSMDoRFLPHe-uj4lmMFxiXrBbiaXHE2FaiFMfF5am_Rr13S9R55PQ1WuvOKut0RAkuNUoeBQ1qhebgoLPg0AaS1S5FBCbpgJRfb8DZzBvbawQoDu3axmi9-4hm-XjlQ0IxDd3N8-KJgT7qF-N8Uvz88vnH_HRydv51MZ-dTZRoaJrUhuiOdoSVgkPFjCqbRjBcClE3lPCaq7bGotbQtm3DmeryFjW0MxSwMQLYSfF6p7vpfZSjT1FSXoqac1GxTCx2ROfhQm6CXUO4kR6svN3wYSkhJKt6LbnidVlhUhPgvDW87UhNK6OyWm1aIFnr03hbTlx3KnsToD8QPTxxdiWX_resBM7CNAu8GwWCvxp0TDL7p3Tfg9N-uH13xTCtmjKjb_5BH85upJaQE7DO-Hyv2orKmeCY8ZKWTaamD1B5dHptVS6q7X8eBrw_CMhM0n_SEoYY5eL7t_9nz38dsm_32JWGPq2i74eUSygegnwHquBjDNrcm0yw3Bb0nRty2xNy7Ikc9mr_g-6D7pqA_QX-AAXy</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2456844673</pqid></control><display><type>article</type><title>How long do new medicines take to reach Canadian patients after companies file a submission: A cohort study</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS)</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Lexchin, Joel</creator><contributor>Postma, Maarten</contributor><creatorcontrib>Lexchin, Joel ; Postma, Maarten</creatorcontrib><description>Studies of the delay between when companies file a New Drug Submission (NDS) and when drugs reach Canadian patients typically focus on the time in the regulatory review process and do not analyze the time between when approval is granted and the drug is available for purchase (company decision time). This study looks at the length of the two different time periods. Secondarily, it examines whether there is a difference in these time periods for drugs that received a standard review and those that received an expedited review.
A list of all New Active Substances approved in Canada between January 1, 2014 and December 31, 2018 was compiled and the dates when the companies applied for a NDS, the dates when the drugs received a market authorization (Notice of Compliance, NOC) and whether the drugs received a standard review or an expedited review were recorded. The date of original marketing comes from Health Canada's Drug Product Database. Times in days were calculated between NDS and NOC (review time), between NOC and the marketing date (company decision time) and between NDS and the marketing date (total time). The company decision time as a percent of the total time was calculated for all drugs. Times were compared between standard and expedited review drugs using a two-tailed t-test.
One hundred and fifty-seven drugs were analyzed, 98 had a standard review and 59 had a priority review. Over 18% of the total time was due to company decisions. All three times were significantly lower for expedited review drugs versus standard review drugs as was the percent of total time due to company decision- 14.4% (95% CI 11.0, 17.8) versus 21.2% (95% CI 17.6, 24.8), p = 0.0102 (t-test).
Over 18% of the total time between when companies file for drug approval until the drug is available is due to decisions made by companies. Company decision times are shorter for drugs with expedited approvals compared to drugs with standard approvals.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0240966</identifier><identifier>PMID: 33137156</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Annual reports ; Biological products ; Biology and Life Sciences ; Canada ; Cohort analysis ; Cohort Studies ; Decisions ; Drug approval ; Drug Approval - legislation & jurisprudence ; Drug Approval - methods ; Drug Industry ; Drugs ; Engineering and Technology ; Equipment and supplies ; Forecasts and trends ; Health care industry ; Humans ; Marketing ; Mathematical analysis ; Medicine and Health Sciences ; Pharmaceutical industry ; Pharmacy ; Physical Sciences ; Production management ; Research and Analysis Methods ; Science Policy ; Social Sciences ; Time Factors</subject><ispartof>PloS one, 2020-11, Vol.15 (11), p.e0240966-e0240966</ispartof><rights>COPYRIGHT 2020 Public Library of Science</rights><rights>2020 Joel Lexchin. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Joel Lexchin 2020 Joel Lexchin</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-8f1ed2d13564a73fc5996305668921484cb8068eabbb943cd4842f2df2a0ff6a3</citedby><orcidid>0000-0001-5120-8029</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605702/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605702/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793,79600,79601</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33137156$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Postma, Maarten</contributor><creatorcontrib>Lexchin, Joel</creatorcontrib><title>How long do new medicines take to reach Canadian patients after companies file a submission: A cohort study</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Studies of the delay between when companies file a New Drug Submission (NDS) and when drugs reach Canadian patients typically focus on the time in the regulatory review process and do not analyze the time between when approval is granted and the drug is available for purchase (company decision time). This study looks at the length of the two different time periods. Secondarily, it examines whether there is a difference in these time periods for drugs that received a standard review and those that received an expedited review.
A list of all New Active Substances approved in Canada between January 1, 2014 and December 31, 2018 was compiled and the dates when the companies applied for a NDS, the dates when the drugs received a market authorization (Notice of Compliance, NOC) and whether the drugs received a standard review or an expedited review were recorded. The date of original marketing comes from Health Canada's Drug Product Database. Times in days were calculated between NDS and NOC (review time), between NOC and the marketing date (company decision time) and between NDS and the marketing date (total time). The company decision time as a percent of the total time was calculated for all drugs. Times were compared between standard and expedited review drugs using a two-tailed t-test.
One hundred and fifty-seven drugs were analyzed, 98 had a standard review and 59 had a priority review. Over 18% of the total time was due to company decisions. All three times were significantly lower for expedited review drugs versus standard review drugs as was the percent of total time due to company decision- 14.4% (95% CI 11.0, 17.8) versus 21.2% (95% CI 17.6, 24.8), p = 0.0102 (t-test).
Over 18% of the total time between when companies file for drug approval until the drug is available is due to decisions made by companies. Company decision times are shorter for drugs with expedited approvals compared to drugs with standard approvals.</description><subject>Annual reports</subject><subject>Biological products</subject><subject>Biology and Life Sciences</subject><subject>Canada</subject><subject>Cohort analysis</subject><subject>Cohort Studies</subject><subject>Decisions</subject><subject>Drug approval</subject><subject>Drug Approval - legislation & jurisprudence</subject><subject>Drug Approval - methods</subject><subject>Drug Industry</subject><subject>Drugs</subject><subject>Engineering and Technology</subject><subject>Equipment and supplies</subject><subject>Forecasts and trends</subject><subject>Health care industry</subject><subject>Humans</subject><subject>Marketing</subject><subject>Mathematical analysis</subject><subject>Medicine and Health Sciences</subject><subject>Pharmaceutical industry</subject><subject>Pharmacy</subject><subject>Physical Sciences</subject><subject>Production management</subject><subject>Research and Analysis Methods</subject><subject>Science Policy</subject><subject>Social Sciences</subject><subject>Time Factors</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk11rFDEUhgdRbK3-A9GAIHqxa74mM-OFsCxqFwoFv27DmUyym3Y22SYZa_-92e607EovJBcJyXPe5Lw5pyheEjwlrCIfLvwQHPTTjXd6iinHjRCPimPSMDoRFLPHe-uj4lmMFxiXrBbiaXHE2FaiFMfF5am_Rr13S9R55PQ1WuvOKut0RAkuNUoeBQ1qhebgoLPg0AaS1S5FBCbpgJRfb8DZzBvbawQoDu3axmi9-4hm-XjlQ0IxDd3N8-KJgT7qF-N8Uvz88vnH_HRydv51MZ-dTZRoaJrUhuiOdoSVgkPFjCqbRjBcClE3lPCaq7bGotbQtm3DmeryFjW0MxSwMQLYSfF6p7vpfZSjT1FSXoqac1GxTCx2ROfhQm6CXUO4kR6svN3wYSkhJKt6LbnidVlhUhPgvDW87UhNK6OyWm1aIFnr03hbTlx3KnsToD8QPTxxdiWX_resBM7CNAu8GwWCvxp0TDL7p3Tfg9N-uH13xTCtmjKjb_5BH85upJaQE7DO-Hyv2orKmeCY8ZKWTaamD1B5dHptVS6q7X8eBrw_CMhM0n_SEoYY5eL7t_9nz38dsm_32JWGPq2i74eUSygegnwHquBjDNrcm0yw3Bb0nRty2xNy7Ikc9mr_g-6D7pqA_QX-AAXy</recordid><startdate>20201102</startdate><enddate>20201102</enddate><creator>Lexchin, Joel</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-5120-8029</orcidid></search><sort><creationdate>20201102</creationdate><title>How long do new medicines take to reach Canadian patients after companies file a submission: A cohort study</title><author>Lexchin, Joel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-8f1ed2d13564a73fc5996305668921484cb8068eabbb943cd4842f2df2a0ff6a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Annual reports</topic><topic>Biological products</topic><topic>Biology and Life Sciences</topic><topic>Canada</topic><topic>Cohort analysis</topic><topic>Cohort Studies</topic><topic>Decisions</topic><topic>Drug approval</topic><topic>Drug Approval - legislation & jurisprudence</topic><topic>Drug Approval - methods</topic><topic>Drug Industry</topic><topic>Drugs</topic><topic>Engineering and Technology</topic><topic>Equipment and supplies</topic><topic>Forecasts and trends</topic><topic>Health care industry</topic><topic>Humans</topic><topic>Marketing</topic><topic>Mathematical analysis</topic><topic>Medicine and Health Sciences</topic><topic>Pharmaceutical industry</topic><topic>Pharmacy</topic><topic>Physical Sciences</topic><topic>Production management</topic><topic>Research and Analysis Methods</topic><topic>Science Policy</topic><topic>Social Sciences</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lexchin, Joel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lexchin, Joel</au><au>Postma, Maarten</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>How long do new medicines take to reach Canadian patients after companies file a submission: A cohort study</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2020-11-02</date><risdate>2020</risdate><volume>15</volume><issue>11</issue><spage>e0240966</spage><epage>e0240966</epage><pages>e0240966-e0240966</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Studies of the delay between when companies file a New Drug Submission (NDS) and when drugs reach Canadian patients typically focus on the time in the regulatory review process and do not analyze the time between when approval is granted and the drug is available for purchase (company decision time). This study looks at the length of the two different time periods. Secondarily, it examines whether there is a difference in these time periods for drugs that received a standard review and those that received an expedited review.
A list of all New Active Substances approved in Canada between January 1, 2014 and December 31, 2018 was compiled and the dates when the companies applied for a NDS, the dates when the drugs received a market authorization (Notice of Compliance, NOC) and whether the drugs received a standard review or an expedited review were recorded. The date of original marketing comes from Health Canada's Drug Product Database. Times in days were calculated between NDS and NOC (review time), between NOC and the marketing date (company decision time) and between NDS and the marketing date (total time). The company decision time as a percent of the total time was calculated for all drugs. Times were compared between standard and expedited review drugs using a two-tailed t-test.
One hundred and fifty-seven drugs were analyzed, 98 had a standard review and 59 had a priority review. Over 18% of the total time was due to company decisions. All three times were significantly lower for expedited review drugs versus standard review drugs as was the percent of total time due to company decision- 14.4% (95% CI 11.0, 17.8) versus 21.2% (95% CI 17.6, 24.8), p = 0.0102 (t-test).
Over 18% of the total time between when companies file for drug approval until the drug is available is due to decisions made by companies. Company decision times are shorter for drugs with expedited approvals compared to drugs with standard approvals.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>33137156</pmid><doi>10.1371/journal.pone.0240966</doi><tpages>e0240966</tpages><orcidid>https://orcid.org/0000-0001-5120-8029</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2020-11, Vol.15 (11), p.e0240966-e0240966 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2456844673 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS); PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Annual reports Biological products Biology and Life Sciences Canada Cohort analysis Cohort Studies Decisions Drug approval Drug Approval - legislation & jurisprudence Drug Approval - methods Drug Industry Drugs Engineering and Technology Equipment and supplies Forecasts and trends Health care industry Humans Marketing Mathematical analysis Medicine and Health Sciences Pharmaceutical industry Pharmacy Physical Sciences Production management Research and Analysis Methods Science Policy Social Sciences Time Factors |
| title | How long do new medicines take to reach Canadian patients after companies file a submission: A cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T00%3A27%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=How%20long%20do%20new%20medicines%20take%20to%20reach%20Canadian%20patients%20after%20companies%20file%20a%20submission:%20A%20cohort%20study&rft.jtitle=PloS%20one&rft.au=Lexchin,%20Joel&rft.date=2020-11-02&rft.volume=15&rft.issue=11&rft.spage=e0240966&rft.epage=e0240966&rft.pages=e0240966-e0240966&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0240966&rft_dat=%3Cgale_plos_%3EA640345259%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2456844673&rft_id=info:pmid/33137156&rft_galeid=A640345259&rft_doaj_id=oai_doaj_org_article_4c48570181a44bf4bd1827fc2458fba1&rfr_iscdi=true |